Drug Discovery

New tech promises to change the way drug candidates are selected at the preclinical level to enter into clinical trials—and to maximize their chances of success

Virtual screening of 6,218 drugs and cell-based assays identifies best therapeutic medication candidates

Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators  broaden applicability for addressing safety and efficacy challenges

Industry-approved fluidic-free standard for label-free molecular interaction analysis

New applications also provide a boost for the technique's possible use in subcellular characterization

Demonstrating the novel technique on prexersatib, research team achieves a fully automated six-step synthesis with 65 percent isolated yield within 32 hours

Understanding your digital integration requirements

Funding will accelerate development of the company’s AI-powered antibody drug discovery technology, focused on identifying new therapeutics for cancer, heart, and lung diseases

Vipergen’s Cellular Binder Trap Enrichment® (cBTE) technology provides a robust system to accelerate and improve drug discovery